# Wolverine Stack

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/wolverine-stack/

Also known as: Wolverine blend, BPC-157 + TB-500

## Quick answers

**What is Wolverine Stack?**

A popular recovery-focused blend typically combining BPC-157 and TB-500 for synergistic tissue repair. BPC-157 and TB-500 sold together (typically co-administered or pre-mixed).

**What is in Wolverine Stack?**

Wolverine Stack typically combines BPC-157 and TB-500. Commercial products vary.

**How strong is the evidence for Wolverine Stack?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. BPC-157 and TB-500 (a thymosin β4 fragment) are each supported mainly by animal studies.

**Is Wolverine Stack FDA-approved?**

No. Wolverine Stack is not an approved product; no regulator has reviewed the combination.

**Is Wolverine Stack banned in sport?**

Yes. Wolverine Stack is prohibited in sport by the World Anti-Doping Agency under S0, S2.

**How does Wolverine Stack work?**

The Wolverine Stack combines two complementary healing pathways: BPC-157 activates FAK-paxillin and VEGFR2-mediated angiogenesis while modulating the nitric oxide system, and TB-500 promotes actin-dependent cell migration and integrin-linked kinase activation. Together they address both vascular supply and cellular migration components of tissue repair.

**What is known about the safety of Wolverine Stack?**

Safety evidence for each component comes mainly from animal studies; human safety data are minimal. No combination-specific safety data published.

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** prohibited (S0, S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular
- **Components:** BPC-157, TB-500

## Overview

A popular recovery-focused blend typically combining BPC-157 and TB-500 for synergistic tissue repair. Named for its reputation of accelerating healing from injuries.

## Mechanism

The Wolverine Stack combines two complementary healing pathways: BPC-157 activates FAK-paxillin and VEGFR2-mediated angiogenesis while modulating the nitric oxide system, and TB-500 promotes actin-dependent cell migration and integrin-linked kinase activation. Together they address both vascular supply and cellular migration components of tissue repair.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Synergistic soft tissue repair
- Accelerated tendon and ligament healing
- Reduced inflammation and scar tissue
- Improved joint and connective tissue health

## Safety & unknowns

Safety evidence for each component comes mainly from animal studies; human safety data are minimal. No combination-specific safety data published. Theoretical concerns include TB-500's pro-angiogenic activity. Neither component is FDA-approved, and both are prohibited in sport (WADA).

## Studies

- Sikiric P, Rucman R, Turkovic B, et al. (2018). *Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing*. Current Pharmaceutical Design. Review. https://pubmed.ncbi.nlm.nih.gov/29879879/
  Review of the BPC-157 component by its originating group, summarizing animal studies of endothelial protection, thrombosis, and gastrointestinal healing.
- Bock-Marquette I, Saxena A, White MD, et al. (2004). *Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair*. Nature. Preclinical. https://pubmed.ncbi.nlm.nih.gov/15565145/
  Mouse and cell study on full-length thymosin β4 (the parent protein of the TB-500 fragment) showing it promoted cardiomyocyte migration and survival via integrin-linked kinase and improved cardiac function after coronary ligation.

## Status sources

- [Review of BPC-157, thymosin β4 and TB-500 evidence in orthopaedics (JAAOS 2026)](https://pubmed.ncbi.nlm.nih.gov/42937313/)
- [WADA 2026 Prohibited List — BPC-157 named under S0; TB-500 under S2](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.